Timothée Olivier, Medical Oncologist and Attending Physician at the Oncology Division of Geneva University Hospital in Switzerland, shared a post on X:
“In May 2026, even the NCCN does NOT recommend daratumumab as a preferred option in high-risk smoldering myeloma!
W/ Sunny Kim and Vinay Prasad, we explain why observation should remain the standard of care in high-risk Smoldering Myeloma.”
Title: Evolving challenges in smoldering myeloma trials: shifting endpoint measurement and definitions
Authors: Myung Sun Kim, Vinay Prasad, Timothée Olivier
Read the Full Article.
Other articles featuring T. Olivier on OncoDaily.
